Preoperative serum thymidine kinase activity as novel monitoring, prognostic, and predictive biomarker in pancreatic cancer

• Verfasst von: Felix, Klaus M. [VerfasserIn]
• Verfasst von: Hinz, Ulf [VerfasserIn]
• Verfasst von: Dobiasch, Sophie [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Verfasst von: Bergmann, Frank [VerfasserIn]
• Verfasst von: Neumüller, Magnus [VerfasserIn]
• Verfasst von: Gronowitz, Simon [VerfasserIn]
• Verfasst von: Bergqvist, Mattias [VerfasserIn]
• Verfasst von: Strobel, Oliver [VerfasserIn]
• Titel: Preoperative serum thymidine kinase activity as novel monitoring, prognostic, and predictive biomarker in pancreatic cancer
• Verf.angabe: Klaus Felix, PhD, Ulf Hinz, MSc, Sophie Dobiasch, MD, Thilo Hackert, MD, Frank Bergmann, MD, Magnus Neumüller, PhD, Simon Gronowitz, PhD, Mattias Bergqvist, BSc, and Oliver Strobel, MD
• Jahr: 2018
• Jahr des Originals: 2017
• Umfang: 8 S.
• Fussnoten: Accepted October 17, 2017 ; Gesehen am 04.05.2020
• Titel Quelle: Enthalten in: Pancreas
• Ort Quelle: Philadelphia, Pa. : Lippincott Williams & Wilkins, 1986
• Jahr Quelle: 2018
• Band/Heft Quelle: 47(2018), 1, Seite 72-79
• ISSN Quelle: 1536-4828
• DOI: doi:10.1097/MPA.0000000000000966
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1697014003

Abstract

Objective: The aim of the study was to investigate serum thymidine kinase 1 (S-TK) activity as a diagnostic and prognostic marker for patients with pancreatic ductal adenocarcinoma (PDAC). Methods: Using the sensitive TK activity assay DiviTum, preoperative serum samples from 404 PDAC, 28 chronic pancreatitis, and 25 autoimmune pancreatitis patients and 83 healthy volunteers were analyzed. The preoperative S-TK activities of 54 PDAC patients who received neoadjuvant therapy (nTx) were also compared with those of 258 PDAC patients who did not receive nTx. Results: The preoperative S-TK activities of PDAC patients were significantly higher and discriminatory from autoimmune and chronic pancreatitis patients and control groups. The S-TK activity in PDAC patients was associated with overall survival. Patients with S-TK activity of less than 80 Du (DiviTum units)/L demonstrated median survival of 20.3 months with an estimated 18.0% 5-year survival rate; for S-TK activity of 80 Du/L or greater, median survival was 15.1 months with a 6.8% 5-year survival rate. For early-stage PDAC, these differences were even more pronounced. The S-TK activity in the nTx group was significantly higher than that in the group not receiving nTx. Conclusions: Pancreatic ductal adenocarcinomas reveal a significant increase in S-TK activity, which is associated with overall survival, especially in early tumor stages. Serum thymidine kinase 1 activity may be a useful parameter for monitoring nTx efficacy.